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Abstract
Background: Coincident with the advent of mammography screening, breast carcinoma in situ
has increased in the US population.
Methods: We conducted a prospective cohort study of all women presenting with primary breast
cancer, aged 21–94, and biopsy confirmed Stage 0-IV from 1990–2005 identified and tracked by our
registry. Clinical presentation characteristics including age, race, TNM stage, family and pregnancy
history, histologic type and method of detection by patient (PtD), physician (PhysD) or
mammography (MgD) were chart abstracted at time of diagnosis. Cases with unknown or other
method of detection (n = 84), or unusual cell types (n = 26) were removed (n = 6074).
Results: From 1990 to 1998 the percentage of PtD and MgD cases was roughly equivalent. In 1999
the percentage of MgD cases increased to 56% and PtD dropped to 37%, a significant 20%
differential, constant to 2005 (Pearson chi square = 120.99, p < .001). Overall, percent TNM stage
0 (breast carcinoma in situ) cases increased after 1990, percent stage I and III cases declined, and
stage II and IV cases remained constant (Pearson chi square = 218.36, p < .001). Increase in MgD
over time differed by age group with an 8.5% increase among women age 40–49 and 12% increase
among women age 50–95. Women age 21–39 rarely had MgD BC. In forward stepwise logistic
regression modeling, significant predictors of MgD BC by order of entry were TNM stage, age at
diagnosis, diagnosis year, and race (chi square = 1867.56, p < .001).
Conclusion: In our cohort the relative proportion of mammography detected breast cancer
increased over time with a higher increase among women age 50+ and an increase of breast
carcinoma in situ exclusively among MgD cases. The increase among women currently targeted by
mammography screening programs (age ≥ 50) combined with an increase of breast carcinoma in
situ most often detected by mammography screening indicates a possible incidence shift to lower
stage breast cancer as a result of mammographic detection.
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Background
Breast cancer is the most prevalent and incident type of
cancer among women in the United States [1]. In 2003,
breast cancer composed 41% of all prevalent cancer cases.
Mammography techniques for identification of breast
cancer were first developed in the 1960s, the results of
mammography screening programs were first published
in the 1970s, and recommended screening guidelines
were developed in the 1980s [2-5]. Screening guidelines
have undergone changes over the past ten years and con-
tinue to change almost annually depending on interpreta-
tion of published literature. The decrease in mortality risk
among screen detected breast cancers has been found to
be attributable to a shift to earlier stage and a more favo-
rable prognosis [6-8].
In spite of strong scientific evidence supporting the value
of mammography screening, a budget cut to the National
Breast Cancer and Cervical Cancer Early Detection Pro-
gram was proposed in 2006 [9]. In 2007 the American
College of Physicians issued recommendations advising
women age 40–49 to obtain a clinical assessment of risk
before undergoing mammography screening [10]. Rec-
ommendations for mammography screening among
women aged 70 and older are being reconsidered and the
value of mammography screening in older women is
being questioned [11,12]. Self breast exam and clinical
breast exam have both been questioned as viable screen-
ing methods with changing recommendations for their
use as screening tools over the past 15 years [13-15].
Table 1: Patient/tumor characteristics by mammography detection (n = 6074)
Variable MgD = no* MgD = yes Chi square p value
N (%) N (%)
(n = 2884) (n = 3190)
Age Row % Row %
21–39 427 (88.4%) 56 (11.6%) 558.99 p < .001
40–49 868 (60.0%) 578 (40.0%)
50–59 668 (40.1%) 996 (59.9%)
60–69 449 (36.3%) 787 (63.7%)
70–94 472 (37.9%) 773 (62.1%)
Race
White 2448 (46.1%) 2866 (53.9%) 35.33 p < .001
Asian 232 (56.9%) 176 (43.1%)
Black 94 (59.1%) 65 (40.9%)
Other 60 (61.9%) 37 (38.1%)
Diagnosis Year
1990 120 (60.9%) 77 (39.1 %) 98.22 p < .001
1991 137 (54.8%) 113 (45.2%)
1992 132 (53.4%) 115 (46.6%)
1993 154 (55.8%) 122 (44.2%)
1994 162 (54.0%) 138 (46.0%)
1995 157 (52.7%) 141 (47.3%)
1996 168 (52.7%) 151 (47.3%)
1997 209 (54.0%) 178 (46.0%)
1998 230 (53.4%) 201 (46.6%)
1999 193 (44.0%) 246 (56.0%)
2000 191 (42.4%) 260 (57.6%)
2001 166 (39.0%) 260 (61.0%)
2002 190 (41.3%) 270 (58.7%)
2003 210 (42.2%) 288 (57.8%)
2004 250 (42.6%) 337 (57.4%)
2005 215 (42.3%) 293 (57.7%)
TNM stage
0 88 (12.1%) 641 (87.9%) 1269.80 p < .001
I 871 (33.1%) 1758 (66.9%)
II 1161 (64.5%) 640 (35.5%)
III 638 (82.5%) 135 (17.5%)
IV 126 (88.7%) 16 (11.3%)
*combined patient and physician detected breast cancer casesBMC Cancer 2008, 8:131 http://www.biomedcentral.com/1471-2407/8/131
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Our study aims to identify changes and trends in mam-
mography detected breast cancer over time by reviewing
primary breast cancer presentation characteristics at a
population based comprehensive community cancer care
center in a major urban area which is part of the Seattle-
Puget Sound Surveillance Epidemiology and End Results
(SEER) cancer registry program of the National Cancer
Institute [16].
Methods
We conducted a prospective cohort study of all women
presenting with primary breast cancer biopsy confirmed
Stage 0-IV from 1990–2005, identified and tracked by our
registry. The registry contains all newly diagnosed cases
treated at our comprehensive community cancer care
center which includes surgical, oncology and radiation
therapy clinics. The registry contains detailed information
on patient characteristics, method of diagnosis, and stage
at diagnosis. Clinical presentation characteristics includ-
ing age, race, TNM stage, family and pregnancy history,
histologic type and method of detection by patient (PtD),
physician (PhysD) or mammography (MgD) were chart
abstracted at time of diagnosis. Our study contained 6074
cases with unknown or other method of detection (n =
84) and unusual cell types (n = 26) removed.
All data collection was conducted using IRB approved
methods and all registry data is stored in a password pro-
tected HIPAA compliant database. All analyses were con-
ducted using de-identified data as per IRB and HIPAA
guidelines. This project was reviewed and approved by the
Institutional Review Board at our community based
regional cancer center.
Initial breast cancer (BC) detection method information
was obtained by careful review of patient medical records
by a certified cancer registrar. The three detection methods
were mammography (MgD), physician exam (PhysD) or
patient detection (PtD). A mammography detected breast
cancer refers to disease discovered by routine mammogra-
phy in the absence of complaints or known physical find-
ings. The mammogram could have been done as part of a
screening program or as a repeat mammogram to verify a
previous equivocal mammography finding (diagnostic).
Physician detection is defined as initiation of work up for
breast cancer by findings discovered by the physician at
routine visit or visit for other problems. Patient detected
was assigned if the patient detected breast symptoms such
as a palpable lump, pain, swelling or bleeding which
prompted her to schedule a doctor visit. Patients with self
detected tumors may have subsequently had a mammo-
gram or ultrasound done but would still be designated as
patient detected BC. The detection method designation
was only made when it was certain from the record. AJCC
Cancer Staging Manual 6th edition categories and defini-
tions were used for tumor, nodes and metastatic (TNM)
cancer staging for all years [17].
SPSS version 14 was used for all statistical analysis [18].
Pearson chi square tests were used for bivariate analysis of
dichotomous variables and analysis of variance was used
for mean comparisons. All p values are two tailed. Test for
trend was run using the binary logistic regression model
to produce a p value of the effect of year on detection
method [19]. Forward stepwise regression was used for
multivariate modeling with mammography detection
compared to manually detected BC by patient or physi-
cian, as the outcome of interest.
Our institution has been a contributor to the Seattle-Puget
Sound SEER registry since 1974–1975. SEER*Stat was
Number of cases by detection method by diagnosis year (n =  6074) Figure 2
Number of cases by detection method by diagnosis 
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Change in detection method by diagnosis year (n = 
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used to review SEER modified AJCC 3rd edition (1988+)
stage at diagnosis results for the 13 county Seattle-Puget
Sound SEER-9 data by year for comparison to our institu-
tions data [20]. A frequency matrix was run using Seattle
(Puget Sound) registry and 'breast' site code by year of
diagnosis 1990–2002 (n = 42,857) from the SEER limited
use file, April 2007.
Results
From 1990 to 2005, 6074 breast cancer (BC) cases were
diagnosed and treated at our institution. Mean age at diag-
nosis was 57 years ranging from 21 to 94 years. Mean age
at diagnosis increased from 56.48 years in 1990–1998 to
mean age of 57.68 years in 1999–2005 (F statistic = 12.40,
p < .001). Percent Asian, African-American, Hispanic and
other non-white race increased from 8.2% in the 1990s to
13.5% in the years 1999 to 2005 (Pearson chi square test
= 69.00, p < .001) (table 1).
From 1990 to 1998 the percentage of PtD and MgD were
roughly equivalent, 45% PtD and 46% MgD. In 1999 the
percentage of MgD cases increased to 56% and PtD
dropped to 37%, a significant 20% differential that
remained constant from 1999 to 2005 (Pearson chi
square = 120.99, p < .001) (figure 1 and table 1). The
absolute number of PtD cases increased after 1996 and
remained relatively constant from 1997 to 2005 with an
average of 179 PtD cases per year (figure 2). A test for
trend using the p value of the effect of year from the binary
logistic regression model of the detection method (mam-
mography detected yes/no) on year was significant, p <
.001. The relative percentage of physician detected cases
declined from 9.8% in 1993 to 3.7% in 2005 but the
absolute number remained constant at approximately 26
cases per year (figure 2).
Including all detection methods, the relative percentage of
TNM stage 0 cases increased after 1990, the percentage of
stage I and III cases declined and the percentage of stage II
and IV cases remained constant (Pearson chi square =
218.36, p < .001) (figure 3). TNM stage 0 cases in our
cohort were all ductal or lobular carcinoma in situ (DCIS,
DCIS/LCIS, or LCIS). Histologic type differed significantly
by detection method with BC in situ primarily detected by
mammography, vs. patient or physician detected cases
(table 2). Breast carcinoma in situ increased from 7.9% of
all cases in 1990–1998 to 15.3% in 1999–2005 with a
steady increase in rate annually as shown in figure 3. The
majority of women with TNM stage 0 BC were treated
with lumpectomy and radiation (85.6%) with 14.4%
receiving mastectomies. When MgD and PtD BC were
analyzed separately the increase in TNM stage 0 BC and
decrease in stage I BC over time was found to be primarily
in the MgD group (MgD chi square test for trend = 152.41,
p < .001) (figures 4 and 5).
Half as many of the MgD in situ BC cases had mastecto-
mies (13%) compared to 26% of the patient and physi-
cian detected tumors (Pearson chi square = 11.44, p <
.001). Of 5843 women with tumor size recorded, 68% of
the MgD tumors were less than or equal to 1.5 cm and
69% of the PtD and PhysD tumors were larger than 1.5 cm
(Pearson chi square = 800.89, p < .001). The MgD in situ
BC tumors were significantly smaller, mean tumor size
equal to 1.89 cm, compared to 2.49 cm for the PhysD in
situ BC and 3.17 cm for the PtD in situ BC tumors (F sta-
tistic = 11.17, p < .001). Only 1.8% of the MgD cases were
age 21–39 (n = 56) so age 21–39 year olds were not ana-
lyzed for tumor size change over time. By diagnosis year,
change in tumor size over time for women age 40–49
(18%, n = 546) and age 50+ (80%, n = 2437) were the fol-
lowing: 1) age 40–49, no significant change in tumor size
over time (F statistic .857, p=.613), and 2) age 50–94 sig-
Patient detected breast cancer: TNM stage by diagnosis year  (n = 2466) Figure 4
Patient detected breast cancer: TNM stage by diag-
nosis year (n = 2466).
All detection method breast cancer: TNM stage by diagnosis  year (n = 6074) Figure 3
All detection method breast cancer: TNM stage by 
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nificant change in tumor size over time with an increase
in mean size from 1.22 cm in 1990 to 1.63 cm in 2005 (F
statistic = 3.53, p < .001). The largest increase in percent-
age of MgD cases over time was among women aged 50–
95 (12%) followed by an increase of 8.5% among women
aged 40–49, with no increase in MgD BC among women
21–39 comparing time periods 1990–1998 and 1999–
2005. Increase in mammography detected breast cancer
did not differ by race over time. Seattle-Puget Sound
SEER-9 registry data for 1990–2002 by TNM stage had a
similar increase in TNM stage 0 BC relative to other TNM
stage BC increasing from 12% of the total in 1990 to 20%
in 2002 (n = 42,857) (figure 6).
In forward stepwise regression analysis with mammogra-
phy detection as the outcome of interest, order of entry
into the model by significance to the outcome was 1)
TNM stage, 2) patient age, 3) diagnosis year, and 4)
patient race. Women diagnosed between 1999 and 2005
were 1.48 times more likely to have breast cancer found
by mammography (95% CI = 1.32, 1.67, p value < .001)
in a model corrected for TNM stage, patient age and race.
Factors associated with mammography detected BC were
1) stage 0 disease (BC in situ), 2) 50+ years of age, 3) later
diagnosis years, 1999 to 2005 compared to 1990–1998,
and 4) white race designation (table 1).
Discussion
In our community based cohort of breast cancer registry
cases we observed a steady rate of mammography detected
breast cancer from 1990 to 1998 that increased signifi-
cantly from 1999 to 2005. A significant increase in TNM
Stage 0 (in situ) breast cancer was coincident with the
increase in MgD BC from a low of 3% in 1990 to a high of
23% in 2005, averaging 8% from 1990 to 1998 and
increasing to an average of 15% from 1999 to 2005. The
shift to more cases of breast carcinoma in situ over time
was exclusively in the mammography detected BC group.
Mammography detected breast cancer was found more
often in women of white race and was most often less
than 1.5 cm in size. Year of diagnosis was a significant pre-
dictor of mammography detection indicating an increas-
ing trend towards mammography detection after 1998.
We also observed a steady increase in absolute number of
breast cancer cases presenting to our institution with the
number of physician and patient detected cases remaining
constant but an increasing number of mammography
detected cases.
Our study is composed of women presenting with a breast
cancer diagnosis and detection method identified as
patient, mammography or physician. From available
medical records we were not able to distinguish if mam-
mography detected cases had participated in regular
scheduled mammography screening. In the patient
detected breast cancer group we were not able to distin-
guish between detection by formally trained self breast
exam or by incidental findings and we do not know if or
when they had prior mammograms. Therefore the patient
detected breast cancer group may contain interval cancers
in women who were in between mammography screen-
ings but also could contain women who do not have reg-
ular mammography screening done.
Nationally there has been a significant increase in the
number of women ≥ 40 years of age reporting 'having had
Table 2: Histologic type by mammography detection (n = 6074)
MgD = no* MgD = yes Chi square p value
N (%) N (%)
(n = 2884) (n = 3190)
row % row %
Carcinoma NOS 37 (84%) 7 (16%) 518.12 .000
Colloid/Mucinous 43 (43%) 58 (57%)
DCIS 86 (12%) 610 (88%)
DCIS/LCIS 0 10 (100%)
LCIS 3 (18%) 14 (82%)
[BC in situ, all types] [89 (12%)] [634 (88%)]
Ductal 2222 (52%) 2035 (48%)
Lobular 297 (55%) 242 (45%
Lobular/Ductal 120 (52%) 109 (48%)
Papillary 10 (40%) 15 (60%)
Medullary 27 (90%) 3 (10%)
Metaplastic 18 (72%) 7 (28%)
Tubular 21 (21%) 80 (79%)
*combined patient and physician detected breast cancer casesBMC Cancer 2008, 8:131 http://www.biomedcentral.com/1471-2407/8/131
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a mammogram in the past 2 years' between 1991 and
2001, while more recent results from the Behavioral Risk
Factor Surveillance System (BRFSS) identify a slight
decline of 2% from 2000 (76.4%) to 2005 (74.6%)
[21,22]. The report of a sustained increase in the number
of women receiving screening mammograms coincides
with our observation of a steady increase in the percentage
and number of mammography detected breast cancers.
The observed increase of in situ breast cancer over time
among MgD BC cases is remarkable and significant.
Although our cohort is relatively small, our observed
trends mirror those of the larger geographic area of which
we are a subset indicating generalizability of our results.
An increase in DCIS over time in the United States has
been reported from SEER data [23-25]. As detection
method information is not available from SEER data this
is the first report to link an observed increase in breast car-
cinoma in situ directly to mammography detection, con-
firming previous hypotheses [26]. A stage shift in which
more breast cancer would be detected at an earlier stage
i.e. a smaller size with participation in mammography
screening programs was predicted by Tabar et al and has
been observed in the Swedish Two-County study of mam-
mography screening programs [27]. Recently a decline in
the rate of invasive breast cancer incidence was reported
from Surveillance, Epidemiology and End Results (SEER)
cancer registry data for 2003 among women aged >50
years [28]. This observed decline has been attributed to
the contemporaneous decline in hormone replacement
therapy use [29]. Alternatively the observed decline in
invasive breast cancer could be at least partially attributa-
ble to an increase in mammography detected breast can-
cer with more cases of BC in situ and fewer cases of
invasive breast cancer.
In our cohort the majority (>80%) of advanced stage BC
were in the patient or physician detected groups.
Advanced breast cancer (TNM stage III and IV) was fairly
constant over time in our cohort which may be due to 1)
patient detected breast cancer in young women not eligi-
ble for screening, 2) patient detected breast cancer in
women who may not participate in a screening program,
3) patient detected interval breast cancer of an aggressive
nature in women who may participate in a mammogra-
phy screening program, and 4) BC not detectable by
mammography. Factors associated with patient detected
breast cancer are addressed in a previous paper by the
same authors [15].
Conclusion
In our cohort we observed an increase in the relative pro-
portion of mammography detected breast cancer over
time with a higher relative increase among women age
50+ and an increase of breast carcinoma in situ exclusively
among mammography detected cases. Relative to mam-
mography detection, the number of patient detected
breast cancers also increased over time to a lesser degree
and the number of physician detected breast cancers
remained constant. The increasing representation of
women aged >50 years who are currently targeted by
mammography screening programs combined with an
increase of in situ BC which is more likely to be detected
by mammography screening indicate a partial shift to a
less advanced form of breast cancer. The change over time
to more mammography detected and lower stage breast
cancer may indicate movement towards the achievement
of mammography screening goals. These results support
retention of screening programs and recommendations as
well as increased awareness of the potential importance of
other detection methods.
SEER-9 Seattle-Puget Sound region modified AJCC-3 TNM  stage by diagnosis year (n = 42,857) Figure 6
SEER-9 Seattle-Puget Sound region modified AJCC-3 TNM 
stage by diagnosis year (n = 42,857).
Mammography detected breast cancer: TNM stage by diag- nosis year (n = 3190) Figure 5
Mammography detected breast cancer: TNM stage 
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